ANDA suitable list
Executive Summary
Key has requested that FDA expand the list to include estradiol 0.5 mg oral tablets, theophylline 450 mg controlled-release oral tablets, and a nitroglycerin-containing transdermal infusion system in which the product component system rather than the skin is the rate limiting factor